Source:http://linkedlifedata.com/resource/pubmed/id/10556952
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1999-12-30
|
| pubmed:abstractText |
Seventeen children with advanced myeloid malignancies (induction failure, relapse, myelodysplasia, secondary AML, or CR >1) received thiotepa 750 mg/m2 i.v., busulfan 12 mg/kg or 640 mg/m2 p.o., and cyclophosphamide 120 mg/kg i.v. as a preparative regimen for allogeneic or autologous hematopoietic stem cell (HSC) transplantation. Of the 15 allogeneic transplants, eight were from matched siblings, one was from a mismatched sibling, and six were from unrelated donors. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine or tacrolimus and methotrexate. Regimen-related toxicity was common but tolerable, affecting mainly the skin and gastrointestinal tract. Three patients died early and were not evaluable for engraftment; engraftment occurred in the remaining patients. Nine patients with active disease at the time of transplant were evaluable for response; all achieved remission. With a median follow-up of 40 months (range, 10-71 months), nine patients are alive and disease-free. The 3-year actuarial event-free survival was 51% (95% confidence interval (CI) 27-76%). Seven patients died of transplant-related complications: infection (n = 4), chronic GVHD (n = 1), veno-occlusive disease, VOD, (n= 1) and pulmonary alveolar hemorrhage (n = 1). Only one patient had leukemia relapse and died. We conclude that the use of high-dose thiotepa, busulfan and cyclophosphamide is an effective conditioning regimen for childhood myeloid malignancies and may be tested in patients with less advanced disease (eg CR1).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
947-52
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10556952-Adolescent,
pubmed-meshheading:10556952-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10556952-Busulfan,
pubmed-meshheading:10556952-Child,
pubmed-meshheading:10556952-Child, Preschool,
pubmed-meshheading:10556952-Combined Modality Therapy,
pubmed-meshheading:10556952-Cyclophosphamide,
pubmed-meshheading:10556952-Female,
pubmed-meshheading:10556952-Graft Survival,
pubmed-meshheading:10556952-Graft vs Host Disease,
pubmed-meshheading:10556952-Hematopoiesis,
pubmed-meshheading:10556952-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10556952-Humans,
pubmed-meshheading:10556952-Infant,
pubmed-meshheading:10556952-Leukemia, Myeloid, Acute,
pubmed-meshheading:10556952-Male,
pubmed-meshheading:10556952-Myelodysplastic Syndromes,
pubmed-meshheading:10556952-Thiotepa,
pubmed-meshheading:10556952-Transplantation, Autologous,
pubmed-meshheading:10556952-Transplantation, Homologous,
pubmed-meshheading:10556952-Transplantation Conditioning
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
|
| pubmed:affiliation |
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|